AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24015263 — intervention group
Group type: EXPERIMENTAL
Intervention: Humanlike face display
Number of subjects: 30
Study 24015263 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver face display
Number of subjects: 30
Study 24015263 — intervention group
Group type: EXPERIMENTAL
Intervention: No-face display
Number of subjects: 30
Study 24015263 — intervention group
Group type: COMPARATOR
Intervention: All robot displays
Number of subjects: 30
Study 21327798 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency vibration recovery (LFV-rec) - 20 Hz; 4 mm for 15 min after exercise
Number of subjects: 12
Study 21327798 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (P-rec) - sitting without vibration stimulus for 15 min after exercise
Number of subjects: 12
Study 18635690 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 89
Study 18635690 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 89
Study 18635690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 17191050 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient containing oat extracts
Number of subjects: 173
Study 17191050 — intervention group
Group type: COMPARATOR
Intervention: Control group (no emollient)
Number of subjects: 173
Study 17191050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (emollient and control)
Number of subjects: 173
Study 15056989 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - 1 hour of physical exercise twice a week for 5 months
Number of subjects: 33
Study 15056989 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 33
Study 15523434 — intervention group
Group type: EXPERIMENTAL
Intervention: Oil-based oral spray
Number of subjects: 20
Study 15523434 — intervention group
Group type: COMPARATOR
Intervention: Water-based oral spray (placebo)
Number of subjects: 20
Study 10028949 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 583
Study 10028949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 583
Study 8747042 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (0.5 mg/day s.c.)
Number of subjects: 100
Study 8747042 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose leuprolide acetate depot (1.88 mg s.c.)
Number of subjects: 100
Study 2167804 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 hours of oxygen withdrawal
Number of subjects: 8
Study 2167804 — intervention group
Group type: COMPARATOR
Intervention: Routine oxygen therapy
Number of subjects: 8
Study 6268283 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate course of irradiation (ICI) of 5000 rads in 25 fractions, 200 rads each, in 5 weeks
Number of subjects: 343
Study 6268283 — intervention group
Group type: COMPARATOR
Intervention: Short course of irradiation (SCI) of 4200 rads in 15 fractions, 280 rads each, in 3 weeks
Number of subjects: 343
Study 6268283 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ICI and SCI
Number of subjects: 343
Study 31533737 — intervention group
Group type: EXPERIMENTAL
Intervention: Minneapolis Staple Foods Ordinance (policy requiring food stores to stock minimum quantities and varieties of healthy foods)
Number of subjects: 3039
Study 29851806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross tape applied at 45° to the right of the flexor digitorum superficialis muscle fibers
Number of subjects: 39
Study 29851806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross tape applied at 45° to the left of the flexor digitorum superficialis muscle fibers
Number of subjects: 39
Study 29851806 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified O‐ring test
Number of subjects: 39
Study 29851806 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal pinch strength using pinch gauge
Number of subjects: 39
Study 26728048 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated PLF
Number of subjects: 40
Study 26728048 — intervention group
Group type: COMPARATOR
Intervention: Conventional PLF
Number of subjects: 40
Study 25240708 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to a 10‐min audiotape of infant crying
Number of subjects: 111
Study 25240708 — intervention group
Group type: COMPARATOR
Intervention: Listening to a 10‐min audiotape of infant cooing
Number of subjects: 111
Study 21868743 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen replacement therapy, aerobic physical activity, tadalafil administration
Number of subjects: 120
Study 21868743 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (PSV <25 cm/s)
Number of subjects: 120
Study 21868743 — intervention group
Group type: COMPARATOR
Intervention: Patients with AED
Number of subjects: 120
Study 20200926 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN 5 mg/day
Number of subjects: 1099
Study 20200926 — intervention group
Group type: EXPERIMENTAL
Intervention: ALN 10 mg/day
Number of subjects: 1099
Study 20200926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1099
Study 17698837 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) as a primary endpoint
Number of subjects: 112
Study 17698837 — intervention group
Group type: EXPERIMENTAL
Intervention: A priori hypothesis relevant to palliation
Number of subjects: 112
Study 17698837 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically meaningful differences in QoL or symptom scores
Number of subjects: 112
Study 17698837 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of differences between mean or median scores
Number of subjects: 112
Study 17698837 — intervention group
Group type: EXPERIMENTAL
Intervention: Definition of palliative response
Number of subjects: 112
Study 17698837 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quality of studies
Number of subjects: 112
Study 17698837 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in methodology and reporting over time
Number of subjects: 112
Study 16230122 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (0.4 mg daily)
Number of subjects: 60
Study 16230122 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (deflazacort, 30 mg daily) plus tamsulosin
Number of subjects: 60
Study 12460529 — intervention group
Group type: EXPERIMENTAL
Intervention: Website condition
Number of subjects: 30
Study 10482144 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-mm NIR stent
Number of subjects: 280
Study 10482144 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-mm NIR stent
Number of subjects: 280
Study 10482144 — intervention group
Group type: COMPARATOR
Intervention: Palmaz-Schatz stent
Number of subjects: 280
Study 7756099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous frusemide: 40 mg bolus then 40 mg h‐1 for 3 h
Number of subjects: 8
Study 7756099 — intervention group
Group type: COMPARATOR
Intervention: Captopril: two 12.5 mg oral doses separated by 2 h
Number of subjects: 8
Study 7756099 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dosing: first captopril dose preceded the frusemide bolus by 30 min
Number of subjects: 8
Study 7756099 — intervention group
Group type: COMPARATOR
Intervention: Frusemide alone
Number of subjects: 8
Study 7756099 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide with captopril
Number of subjects: 8
Study 31592692 — intervention group
Group type: EXPERIMENTAL
Intervention: Epigenetic age acceleration measures using DNA methylation from blood
Number of subjects: 0
Study 31592692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic epigenetic age acceleration
Number of subjects: 0
Study 31592692 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrinsic epigenetic age acceleration
Number of subjects: 0
Study 31592692 — intervention group
Group type: EXPERIMENTAL
Intervention: PhenoAge Acceleration
Number of subjects: 0
Study 28089163 — intervention group
Group type: COMPARATOR
Intervention: Volar locking plates
Number of subjects: 50
Study 28089163 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragment-specific fixation
Number of subjects: 50
Study 26786987 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen therapy with Venturi mask for first 12 hours of admission
Number of subjects: 52
Study 26786987 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 52
Study 23502992 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based disease management
Number of subjects: 161
Study 23502992 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 161
Study 21482635 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention of 225 min/week
Number of subjects: 320
Study 21482635 — intervention group
Group type: COMPARATOR
Intervention: Control group maintaining usual activity levels
Number of subjects: 320
Study 19690345 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention plus quadriceps strengthening exercises
Number of subjects: 389
Study 19690345 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention alone
Number of subjects: 389
Study 19690345 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps strengthening exercises alone
Number of subjects: 389
Study 19690345 — intervention group
Group type: COMPARATOR
Intervention: Advice leaflet only (control group)
Number of subjects: 389
Study 16970537 — intervention group
Group type: EXPERIMENTAL
Intervention: Gargling with tea catechin extract solution (200 microg/mL catechins, 60% epigallocatechin gallate), performed three times daily for 3 months.
Number of subjects: 124
Study 16970537 — intervention group
Group type: COMPARATOR
Intervention: Gargling without tea catechin extracts (control group), performed three times daily for 3 months.
Number of subjects: 124
Study 10999673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg
Number of subjects: 729
Study 10999673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 729
Study 10999673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 729
Study 10999673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 729
Study 9076204 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry in normal subjects
Number of subjects: 78
Study 9076204 — intervention group
Group type: COMPARATOR
Intervention: Scanning laser polarimetry in patients with OHT
Number of subjects: 78
Study 9076204 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry in normal subjects (inferior retina)
Number of subjects: 78
Study 9076204 — intervention group
Group type: COMPARATOR
Intervention: Scanning laser polarimetry in patients with OHT (inferior retina)
Number of subjects: 78
Study 9076204 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry in normal subjects (superior retina)
Number of subjects: 78
Study 9076204 — intervention group
Group type: COMPARATOR
Intervention: Scanning laser polarimetry in patients with OHT (superior retina)
Number of subjects: 78
Study 8363079 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 micrograms)
Number of subjects: 54
Study 8363079 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (10 mg)
Number of subjects: 54
Study 8363079 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 54
Study 8363079 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (37.5 micrograms)
Number of subjects: 54
Study 8363079 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (75 micrograms)
Number of subjects: 54
Study 8363079 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (75 and 150 micrograms)
Number of subjects: 54
Study 3752350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenox Hill Derotation Brace (LHB)
Number of subjects: 10
Study 3752350 — intervention group
Group type: COMPARATOR
Intervention: No brace condition
Number of subjects: 10
Study 31164059 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for six months
Number of subjects: 31
Study 31164059 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 31
Study 28738266 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 205
Study 28738266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study 26552175 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT low dose (1.89 x 10(‐4) mol x L(‐1) + 20 μg x L(‐1) TGF‐β1)
Number of subjects: 6
Study 26552175 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT medium dose (3.78 x 10(‐4) mol x L(‐1) + 20 μg x L(‐1) TGF‐β1)
Number of subjects: 6
Study 26552175 — intervention group
Group type: EXPERIMENTAL
Intervention: OMT high dose (7.56 x 10(‐4) mol x L(‐1) + 20 μg x L(‐1) TGF‐β1)
Number of subjects: 6
Study 26552175 — intervention group
Group type: EXPERIMENTAL
Intervention: SB203580 (p38MAPK blocking agent, 1 x 10(‐5) mol x L(‐1) + 20 μg x L(‐1) TGF‐β1)
Number of subjects: 6
Study 26552175 — intervention group
Group type: COMPARATOR
Intervention: Control group (serum free DMEM)
Number of subjects: 6
Study 26552175 — intervention group
Group type: EXPERIMENTAL
Intervention: Model group (20 μg x L(‐1) TGF‐β1)
Number of subjects: 6
Study 23863086 — intervention group
Group type: EXPERIMENTAL
Intervention: Kuan-Sin-Yin (KSY) decoction
Number of subjects: 57
Study 23863086 — intervention group
Group type: COMPARATOR
Intervention: Control group (KSY diluted 16 times)
Number of subjects: 57
Study 22042952 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months of androgen suppression therapy (AST)
Number of subjects: 761
Study 22042952 — intervention group
Group type: COMPARATOR
Intervention: 3 or 4 months of androgen suppression therapy (AST)
Number of subjects: 761
Study 22042952 — intervention group
Group type: EXPERIMENTAL
Intervention: AST duration of 6 months
Number of subjects: 761
Study 22042952 — intervention group
Group type: COMPARATOR
Intervention: AST duration of 3 or 4 months
Number of subjects: 761
Study 18648865 — intervention group
Group type: EXPERIMENTAL
Intervention: Gow-Gates mandibular block with device
Number of subjects: 90
Study 18648865 — intervention group
Group type: COMPARATOR
Intervention: Gow-Gates mandibular block without device (control group)
Number of subjects: 90
Study 16543470 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic chemotherapy
Number of subjects: 0
Study 14529705 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting tasks (females with CAH)
Number of subjects: 128
Study 14529705 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting tasks (males with CAH)
Number of subjects: 128
Study 14529705 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rotations tasks (females with CAH)
Number of subjects: 128
Study 14529705 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rotations tasks (males with CAH)
Number of subjects: 128
Study 14529705 — intervention group
Group type: COMPARATOR
Intervention: Targeting tasks (unaffected females)
Number of subjects: 128
Study 14529705 — intervention group
Group type: COMPARATOR
Intervention: Targeting tasks (unaffected males)
Number of subjects: 128
Study 10905240 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (omeprazole 20 mg, clarithromycin 250 mg, and tinidazole 500 mg, each twice daily for 7 days)
Number of subjects: 2324
Study 10905240 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2324
Study 10905240 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 2324
Study 10905240 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment and placebo
Number of subjects: 2324
Study 8730248 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine 150 mg at 07.30 h (early evening)
Number of subjects: 24
Study 8730248 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine 150 mg at 22.00 h (bedtime)
Number of subjects: 24
Study 8730248 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 1417177 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐hGH (0.1 mg/kg/day or 0.2 mg/kg/day) + insulin (1 mU/kg/minute)
Number of subjects: 28
Study 1417177 — intervention group
Group type: COMPARATOR
Intervention: insulin (1 mU/kg/minute)
Number of subjects: 28
Study 3903581 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine hydrochloride
Number of subjects: 100
Study 3903581 — intervention group
Group type: COMPARATOR
Intervention: Alpha-methyldopa
Number of subjects: 100
Study 31923070 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid use disorder treatment
Number of subjects: 260
Study 29661095 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sensory relearning
Number of subjects: 20
Study 29661095 — intervention group
Group type: COMPARATOR
Intervention: Traditional relearning
Number of subjects: 20
Study 28429967 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee arthroscopic surgery combined with a 3-month exercise program
Number of subjects: 150
Study 28429967 — intervention group
Group type: COMPARATOR
Intervention: 3-month exercise program alone (nonsurgery group)
Number of subjects: 150
Study 25786714 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clobetasol 0.05% applied at night
Number of subjects: 60
Study 25786714 — intervention group
Group type: COMPARATOR
Intervention: Systemic mycophenolate mofetil (MMF) 2 g/day
Number of subjects: 60
Study 23743482 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week LSC videos
Number of subjects: 238
Study 23743482 — intervention group
Group type: COMPARATOR
Intervention: 12-week HIV prevention messages (text messages)
Number of subjects: 238
Study 20472399 — intervention group
Group type: EXPERIMENTAL
Intervention: LPD 7/7 (low protein diet providing 0.8 g/kg per day, 7 days a week)
Number of subjects: 52
Study 20472399 — intervention group
Group type: EXPERIMENTAL
Intervention: LPD 6/7 (low protein diet providing 0.8 g/kg per day, 6 days a week)
Number of subjects: 52
Study 18432491 — intervention group
Group type: EXPERIMENTAL
Intervention: LOVIT (outpatient low-vision programme)
Number of subjects: 176
Study 18432491 — intervention group
Group type: COMPARATOR
Intervention: BRC (inpatient blind rehabilitation centres)
Number of subjects: 176
Study 15979226 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (C‐SE) with prior etching using 40% phosphoric acid (K‐etchant)
Number of subjects: 0
Study 15979226 — intervention group
Group type: COMPARATOR
Intervention: Clearfil SE Bond (C‐SE) without prior etching
Number of subjects: 0
Study 15979226 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (C‐SE) with prior etching on dentin
Number of subjects: 0
Study 15979226 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (C‐SE) with prior etching
Number of subjects: 0
Study 15231567 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief anthracycline-based chemotherapy plus high-dose extended irradiation
Number of subjects: 500
Study 15231567 — intervention group
Group type: COMPARATOR
Intervention: Classical Hodgkin lymphoma without mediastinal involvement (cHL without MI)
Number of subjects: 500
Study 11300386 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled epidural analgesia (PCEA) with bupivacaine 1.1 mg/ml and fentanyl 5 microg/ml, bolus of 0.05 ml/kg, lockout interval of 10 min, total dose limit of three bolus doses per hour.
Number of subjects: 54
Study 11300386 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural infusion (EPI) with bupivacaine 1.1 mg/ml and fentanyl 5 microg/ml, continuous infusion of 0.1 ml kg(‐1) h(‐1) and a minimal extra bolus dose of 0.2 ml with the same lockout interval.
Number of subjects: 54
Study 9129064 — intervention group
Group type: EXPERIMENTAL
Intervention: zalcitabine (0.03 mg/kg/day) in combination with zidovudine (720 mg/m2/day)
Number of subjects: 250
Study 9129064 — intervention group
Group type: COMPARATOR
Intervention: zidovudine monotherapy
Number of subjects: 250
Study 8169480 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release
Number of subjects: 71
Study 8169480 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release
Number of subjects: 71
Study 8169480 — intervention group
Group type: COMPARATOR
Intervention: Transbursal endoscopic technique
Number of subjects: 71
Study 8169480 — intervention group
Group type: COMPARATOR
Intervention: Extrabursal endoscopic technique
Number of subjects: 71
Study 3203716 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg oral dose in the fasted state
Number of subjects: 20
Study 3203716 — intervention group
Group type: COMPARATOR
Intervention: Cefixime 400 mg oral dose with a standard breakfast
Number of subjects: 20
Study 3203716 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg oral dose in the fed state
Number of subjects: 20
Study 3203716 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg oral dose in both states
Number of subjects: 20
Study 31743987 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid (COR) injection
Number of subjects: 129
Study 31743987 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 129
Study 31743987 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolotherapy (PRO) injection
Number of subjects: 129
Study 30513882 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfying rehearsal condition
Number of subjects: 128
Study 30513882 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissatisfying rehearsal condition
Number of subjects: 128
Study 30513882 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral rehearsal condition
Number of subjects: 128
Study 30513882 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 128
Study 26694927 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm humidified CO2 insufflation
Number of subjects: 158
Study 26694927 — intervention group
Group type: COMPARATOR
Intervention: Control (no warm humidified CO2 insufflation)
Number of subjects: 158
Study 26694927 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-operation wound edge temperature
Number of subjects: 158
Study 26694927 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (10-year increase)
Number of subjects: 158
Study 26694927 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer diagnosis
Number of subjects: 158
Study 25186739 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of community music training
Number of subjects: 0
Study 25186739 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of community music training
Number of subjects: 0